DE68912882D1 - Wirkstoff-Harzkomplexe mit verzögerter Freigabe. - Google Patents

Wirkstoff-Harzkomplexe mit verzögerter Freigabe.

Info

Publication number
DE68912882D1
DE68912882D1 DE89870168T DE68912882T DE68912882D1 DE 68912882 D1 DE68912882 D1 DE 68912882D1 DE 89870168 T DE89870168 T DE 89870168T DE 68912882 T DE68912882 T DE 68912882T DE 68912882 D1 DE68912882 D1 DE 68912882D1
Authority
DE
Germany
Prior art keywords
drug
active ingredient
delayed release
resin complexes
ingredient resin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89870168T
Other languages
English (en)
Other versions
DE68912882T2 (de
Inventor
William Joseph Kelleher
Anthony Earl Carpanzano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richardson Vicks Inc
Original Assignee
Richardson Vicks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richardson Vicks Inc filed Critical Richardson Vicks Inc
Application granted granted Critical
Publication of DE68912882D1 publication Critical patent/DE68912882D1/de
Publication of DE68912882T2 publication Critical patent/DE68912882T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
DE68912882T 1988-11-02 1989-10-31 Wirkstoff-Harzkomplexe mit verzögerter Freigabe. Expired - Fee Related DE68912882T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/265,910 US4996047A (en) 1988-11-02 1988-11-02 Sustained release drug-resin complexes

Publications (2)

Publication Number Publication Date
DE68912882D1 true DE68912882D1 (de) 1994-03-17
DE68912882T2 DE68912882T2 (de) 1994-06-01

Family

ID=23012384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68912882T Expired - Fee Related DE68912882T2 (de) 1988-11-02 1989-10-31 Wirkstoff-Harzkomplexe mit verzögerter Freigabe.

Country Status (11)

Country Link
US (1) US4996047A (de)
EP (1) EP0367746B1 (de)
JP (1) JP2941314B2 (de)
AT (1) ATE101033T1 (de)
AU (1) AU638420B2 (de)
CA (1) CA2001859C (de)
DE (1) DE68912882T2 (de)
DK (1) DK175659B1 (de)
IE (1) IE62765B1 (de)
NZ (1) NZ231229A (de)
PH (1) PH26699A (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
US5162110A (en) * 1990-12-19 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Binding theophylline to ion exchange resins
AU663695B2 (en) * 1990-12-21 1995-10-19 Richardson-Vicks Inc. Polyamine drug-resin complexes
US5275820A (en) * 1990-12-27 1994-01-04 Allergan, Inc. Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
IT1250736B (it) * 1991-08-01 1995-04-21 Zambon Spa Processo per la preparazione dell'acido 5-(2',4'-difluorofenil) salicilico in forma ii pura
SE9103110D0 (sv) * 1991-10-24 1991-10-24 Kabi Pharmacia Ab New drug formulation
US5492700A (en) * 1991-11-26 1996-02-20 Warner-Lambert Company Process and composition for the development of controlled release gemfibrozil dosage form
IT1252185B (it) * 1991-12-11 1995-06-05 Therapicon Srl Preparazioni farmaceutiche a liberazione programmata
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
CA2063499C (en) * 1992-03-19 1996-06-18 Leon Edward St. Pierre Ingestible polymeric phosphonium salts for the lowering of blood cholesterol
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
TW237386B (de) * 1992-04-15 1995-01-01 Ciba Geigy
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
EP0667148B1 (de) * 1992-11-06 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. Perorale pharmazeutische zubereitung mit freisetzung im unteren verfdauungstrakt
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
USRE39300E1 (en) 1993-01-28 2006-09-19 Virginia Commonwealth University Medical College Of Virginia Inhibiting the development of tolerance to and/or dependence on an addictive substance
CA2122286A1 (en) * 1993-04-28 1994-10-29 Hiroshi Matoba Solid preparation and its production
ZA944949B (en) * 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
EP0664699A1 (de) * 1993-08-13 1995-08-02 Vitaphore Corporation Arzneimittelabgabesystem auf der Basis von Hydrogelmikrokugeln
US5932248A (en) * 1993-11-18 1999-08-03 Paragon Medical Limited Controlled release preparations for cytotoxic or cytostatic drugs
DE4402379C2 (de) * 1994-01-27 1997-09-25 Lohmann Therapie Syst Lts Orale Arzneiform mit sauren Wirkstoffen und Verfahren zu ihrer Herstellung
US6322815B1 (en) 1994-07-22 2001-11-27 W. Mark Saltzman Multipart drug delivery system
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
GB9607955D0 (en) * 1996-04-17 1996-06-19 Tillotts Pharma Ag Hydrophobic carbomer salt compositions
EP0946145B1 (de) * 1996-12-20 2008-09-03 McNeil-PPC, Inc. Durch ionenaustauscherharze verabreichte hustenmittel
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
CA2355829A1 (en) * 1999-01-07 2000-07-13 Louise Templeton Multiparticulate oral dosage forms
HUP0202229A3 (en) * 1999-07-14 2008-10-28 Schering Plough Ltd Oral liquid pharmaceutical compositions containing quinolone derivatives and ion exchange resins as taste mashing
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7067116B1 (en) 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US6855721B1 (en) 2000-07-28 2005-02-15 Indevus Pharmaceuticals, Inc. Methods and compositions for alleviating stuttering
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
JP2005511477A (ja) * 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
US20060198815A1 (en) * 2001-03-19 2006-09-07 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
AU2002363444B2 (en) * 2001-11-09 2007-12-06 Apt Pharmaceuticals, Inc. A method for treating inflammatory bowel disease
MXPA04009701A (es) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Formulaciones de metoprolol de liberacion sostenida.
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
EP1599187A4 (de) 2002-11-26 2007-08-08 Univ Maryland Wässriges arzneistoffabgabesystem mit anhaltenderwirkstofffreigabe für stark wasserlösliche elektrolytika
EP1592453A1 (de) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate aufbau von milnacipran für orale einnahme
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US8008378B2 (en) 2003-07-28 2011-08-30 Novartis Ag Taste-masked composition of cationic exchange resin
CN1845722A (zh) * 2003-09-03 2006-10-11 马林克罗特公司 粒状缓释制剂及其生产
MXPA06003450A (es) 2003-09-26 2006-08-31 Johnson & Johnson Recubrimiento de farmaco que proporciona alta carga del farmaco y metodos para proporcionar el mismo.
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20070232695A1 (en) * 2004-01-28 2007-10-04 Collegium Pharmaceutical, Inc. Gelled Periodontal Anesthetic Preparation
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050226920A1 (en) * 2004-04-13 2005-10-13 Kirk Voelker Method of decreasing nicotine withdrawal symptoms during smoking cessation.
US7429617B2 (en) * 2004-04-27 2008-09-30 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of interstitial cystitis
CN1968697B (zh) * 2004-05-14 2012-05-16 株式会社绿十字 右旋吗啡喃的神经保护特性
WO2005115336A2 (en) * 2004-05-15 2005-12-08 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US9308164B2 (en) * 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
EP1846040A2 (de) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Nicht ionische und nicht wässrige transportelemente zur topischen und oralen verabreichung träger-komplexierter wirkstoffe
EP2361611A3 (de) * 2005-06-09 2011-10-12 Upm Pharmaceuticals, Inc. Wässriges, anhaltend freisetzendes Arzneimittelabgabesystem für stark wasserlösliche, elektrolytische Arzneimittel
JP2008546835A (ja) * 2005-06-28 2008-12-25 ユ セ ベ ソシエテ アノニム 複数の活性薬物−樹脂抱合体
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
CN101253179B (zh) * 2005-09-21 2010-12-29 株式会社钟根堂 S-氯吡格雷的树脂酸盐复合物及其制备方法
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
BRPI0709606B8 (pt) * 2006-03-16 2021-05-25 Tris Pharma Inc suspensão líquida administrável oralmente com características de liberação modificada
US20080044462A1 (en) * 2006-04-06 2008-02-21 Collegium Pharmaceutical, Inc. Delaware Stabilized transdermal bupropion preparations
US20070286903A1 (en) * 2006-06-13 2007-12-13 Becicka Brian T Composition and method for taste masking
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
CN105534936B (zh) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 抗滥用药物、使用方法和制备方法
CN102164589A (zh) * 2008-09-24 2011-08-24 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
US20130177520A1 (en) * 2009-12-31 2013-07-11 Ranbaxy Laboratories Limited Taste masked dosage forms of bitter tasting anti-retroviral drugs
US8470375B1 (en) * 2010-01-05 2013-06-25 Neos Therapeutics, Lp Method of formulating and designing liquid drug suspensions containing ion exchange resin particles
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
EP2726066B1 (de) 2011-06-28 2021-03-31 Neos Therapeutics, LP Dosisformen für amphetamin zur oralen verabreichung
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
US8962687B2 (en) 2012-12-05 2015-02-24 Medicinova, Inc. Method of treating liver disorders
JP2013119550A (ja) 2011-12-08 2013-06-17 Medicinova Inc 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
EP2833868A1 (de) 2011-12-09 2015-02-11 Wockhardt Limited Orales flüssiges konzentrat mit brompheniramin, pseudoephedrin und dextromethorphan
US20150056288A1 (en) * 2011-12-14 2015-02-26 Wockhardt Limited Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
JP2016504413A (ja) * 2013-01-15 2016-02-12 サン・ファーマシューティカルズ・インダストリーズ・リミテッド 安定な組成物を含有するフィンゴリモド
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
ES2843511T3 (es) 2013-07-25 2021-07-19 Medicinova Inc Métodos para reducir las concentraciones en sangre de triglicéridos, colesterol total y lipoproteínas de baja densidad
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015076821A1 (en) * 2013-11-22 2015-05-28 Tris Pharma, Inc. Novel clonidine formulation
US20150321989A1 (en) 2014-05-08 2015-11-12 Medicinova, Inc. Method of treating idiopathic pulmonary fibrosis
US9346754B2 (en) 2014-05-08 2016-05-24 Medicinova, Inc. Method of treating advanced non-alcoholic steatohepatitis
CN106470678A (zh) 2014-06-02 2017-03-01 美迪诺亚公司 抑制或治疗纤维化的方法
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
JP6827924B2 (ja) 2014-11-26 2021-02-10 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラスト及びリルゾールの組み合わせを含む医薬および組成物
MA41152A (fr) * 2014-12-12 2017-10-17 Johnson & Johnson Consumer Inc Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
CN109890371A (zh) 2016-08-26 2019-06-14 斯瑞尼瓦萨饶·韦帕切杜 组合物及其方法
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
EP3737353A1 (de) 2017-12-18 2020-11-18 Tris Pharma, Inc. Pharmazeutische ghb-zusammensetzungen mit einem system zur formung von schwimmenden interpenetrierenden polymernetzwerken
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
EP3727339A1 (de) * 2017-12-22 2020-10-28 DDP Specialty Electronic Materials US, Inc. Pharmazeutische zusammensetzung mit harzteilchen
KR20200106503A (ko) * 2017-12-22 2020-09-14 디디피 스페셜티 일렉트로닉 머티리얼즈 유에스 8 엘엘씨 가교결합된 이온 교환 수지를 함유하는 약학적 조성물
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition
WO2022251464A1 (en) 2021-05-28 2022-12-01 Medicinova, Inc. Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3155590A (en) * 1962-08-02 1964-11-03 Ncr Co Encapsulation process and its product
US3499960A (en) * 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3594470A (en) * 1968-02-19 1971-07-20 Abbott Lab Chewable tablets including coated particles of pseudoephedrine-weak cation exchange resin
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
DE2246037B2 (de) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform
US4221728A (en) * 1977-12-28 1980-09-09 General Electric Company Stabilized polycarbonate compositions
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
JPS6045845B2 (ja) * 1979-10-31 1985-10-12 田辺製薬株式会社 医薬物質含有マイクロカプセルの製法
JPS57197214A (en) * 1981-05-29 1982-12-03 Tanabe Seiyaku Co Ltd Rapid-releasing microcapsule and its preparation
CA1236023A (en) * 1984-07-18 1988-05-03 Yegnaswami Raghunathan Controlled release pharmaceutical preparations
US4847077A (en) * 1984-07-18 1989-07-11 Pennwalt Corporation Controlled release pharmaceutical preparations
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
US4810501A (en) * 1986-06-17 1989-03-07 Warner-Lambert Company Sustained release pharmaceutical preparations
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
US4894239A (en) * 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof

Also Published As

Publication number Publication date
CA2001859A1 (en) 1990-04-02
AU4430689A (en) 1990-05-10
EP0367746A2 (de) 1990-05-09
AU638420B2 (en) 1993-07-01
EP0367746A3 (de) 1991-01-23
DK175659B1 (da) 2005-01-10
IE62765B1 (en) 1995-02-22
US4996047A (en) 1991-02-26
DK546389A (da) 1990-05-03
CA2001859C (en) 1995-10-31
JPH02172912A (ja) 1990-07-04
ATE101033T1 (de) 1994-02-15
PH26699A (en) 1992-09-14
DK546389D0 (da) 1989-11-02
NZ231229A (en) 1992-03-26
JP2941314B2 (ja) 1999-08-25
DE68912882T2 (de) 1994-06-01
EP0367746B1 (de) 1994-02-02
IE893537L (en) 1990-05-02

Similar Documents

Publication Publication Date Title
DE68912882T2 (de) Wirkstoff-Harzkomplexe mit verzögerter Freigabe.
DE69805001T2 (de) Osmotische darreichungsform mit zwei mantelschichten
DE69832816D1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
AU7534087A (en) Sustained release pharmaceutical compositions in oral dosage form
DE69013296T2 (de) Einzeldosen mit verzögerter Arzneistofffreigabe.
DE69109557D1 (de) Überzogene feste Arzneiform mit Verabreichungsmöglichkeit im Dickdarm.
DE69427568T2 (de) Rasch freisetzende Tablettenkerne mit unlöslichen Arzneistoffen und mit einem Retardüberzug
ATE213629T1 (de) Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe
ATE225165T1 (de) Im unteren teil des verdauungstrakts freisetzende pharmazeutische zubereitung in form einer beschichteten kapsel
NL194781B (nl) Farmaceutisch preparaat voor orale toediening dat een cyclosporine bevat.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE231725T1 (de) Pharmazeutische zubereitungen zur oralen verabreichung von molekulares jod
ATE124255T1 (de) Im dickdarm zerfallende, polypeptide enthaltende orale formulierungen.
MY107811A (en) Polyamine drug-resin complexes
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
EP0271151A3 (de) Azumolen-Dosisformen
SE8701077D0 (sv) Pharmaceutical composition
ITRM910550A0 (it) Preparazioni farmaceutiche orali, a base di acidi biliari, a cessione protratta e controllata con le quali e' possibile adottare una sola somministrazione giornaliera
RU93043627A (ru) Фармацевтическая композиция, содержащая комплекс из смолы и полиаминового лекарственного препарата
NO171295C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av et biologisk aktivt konjugert protein
DE3688355T2 (de) Fester Körper mit überzogenem Kern.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee